Briumvi (ublituximab) has been approved by NICE (National Institute for Health and Care Excellence) for people with active relapsing remitting multiple sclerosis. In England and Wales, NICE has ...

Neuraxpharm Group (Neuraxpharm), a leading European specialty pharmaceutical company focused on the treatment of central nervous system (CNS) disorders, today announces that the National Institute for ...

IFN-β and glatiramir acetate are the most widely used licensed disease-modifying treatments in MS. There is a consensus that they are acceptably safe and have partial efficacy, reducing the ...